InsidersTradesSigma
Total declarations
Company
▲ Purchases (15 ops.)
▼ Sales (0 ops.)
Explore the full record of transactions filed by BNP PARIBAS DEVELOPPEMENT SA, Représentant de BNP Paribas Développement au sein des instances de gouvernance de LNA Santé. Officer active across 1 companies, notably LNA SANTE. Cumulatively, 15 disclosures have been published. Total volume traded: €1.1m. The latest transaction was disclosed on 22 October 2024 — Acquisition. Regulator: AMF. The full history is free.
Declarations15 total
€95,7973,993 shares@ €23.99130.039% mcap9.1% of flow
ActionEuronext Paris
2024DD1002198·
Ideal exit: 19 Jul 2025 (T+270)
€154,5866,492 shares@ €23.81180.063% mcap14.6% of flow
ActionEuronext Paris
2024DD1001667·
Ideal exit: 14 Jul 2025 (T+270)
€9,507399 shares@ €23.82780.0039% mcap0.9% of flow
ActionEuronext Paris
2024DD1000962·
Ideal exit: 11 Jul 2025 (T+270)
€54224 shares@ €22.600.0002% mcap0.1% of flow
ActionEuronext Paris
2024DD1000305·
Ideal exit: 6 Jul 2025 (T+270)
€2,329102 shares@ €22.82840.0009% mcap0.2% of flow
ActionEuronext Paris
2024DD999778·
Ideal exit: 1 Jul 2025 (T+270)
€46,2002,000 shares@ €23.100.019% mcap4.4% of flow
ActionEuronext Paris
2024DD999287·
Ideal exit: 29 Jun 2025 (T+270)
€18,497804 shares@ €23.00660.0075% mcap1.7% of flow
ActionEuronext Paris
2024DD997412·
Ideal exit: 20 Jun 2025 (T+270)
€26,5221,100 shares@ €24.1110.011% mcap2.5% of flow
ActionEuronext Paris
2024DD991572·
Ideal exit: 6 May 2025 (T+270)
€35,7631,467 shares@ €24.37830.015% mcap3.4% of flow
ActionEuronext Paris
2024DD990995·
Ideal exit: 2 May 2025 (T+270)
€13,936581 shares@ €23.98610.0057% mcap1.3% of flow
ActionEuronext Paris
2024DD984244·
Ideal exit: 24 Mar 2025 (T+270)
€58,2242,426 shares@ €24.000.024% mcap5.5% of flow
ActionEuronext Paris
2024DD982721·
Ideal exit: 16 Mar 2025 (T+270)
€396,51614,318 shares@ €27.69350.16% mcap37.5% of flow
ActionEuronext Paris
2024DD971981·
Ideal exit: 10 Mar 2025 (T+270)
€71,5432,602 shares@ €27.49530.029% mcap6.8% of flow
ActionEuronext Paris
2024DD971087·
Ideal exit: 7 Mar 2025 (T+270)
€37,7461,488 shares@ €25.36720.015% mcap3.6% of flow
ActionEuronext Paris
2024DD969023·
Ideal exit: 23 Feb 2025 (T+270)
€90,6653,703 shares@ €24.48410.037% mcap8.6% of flow
ActionEuronext Paris
2024DD968252·
Ideal exit: 18 Feb 2025 (T+270)
15 of 15 declarations
About BNP PARIBAS DEVELOPPEMENT SA
BNP Paribas Développement is the long-term investment arm of the BNP Paribas group, active for more than 30 years in the capital of high-performing SMEs and mid-sized companies. In the case of LNA Santé, it acts as a minority shareholder and development partner, with a mandate centered on capital stability, strategic support, and backing for growth or ownership-transfer transactions. Within LNA Santé’s governance framework, BNP Paribas Développement is represented by Julien Marronnier, who sits on the company’s board and/or strategic bodies according to the group’s published reference documents. LNA Santé explicitly describes BNP Paribas Développement as an autonomous subsidiary of BNP Paribas that invests its own funds to support business development and long-term sustainability. LNA Santé is a French healthcare and care-services group dedicated to supporting vulnerable people. Its growth has been built on a family-owned, independent model that has gradually opened up to respected institutional partners. BNP Paribas Développement’s presence in both the shareholding structure and the governance of the company fits that logic: securing the capital base, preserving independent decision-making, and supporting a controlled growth path. The group operates a significant network of healthcare and care establishments in France and Belgium, with a strategy focused on service quality, strong local roots, and continuous organizational improvement. In this context, BNP Paribas Développement’s role can be understood as that of a reference investor committed to sustainable value creation. Its expertise lies in growth financing, executive support, capital structure design, and the preparation of succession or transfer phases. Its involvement with LNA Santé highlights a long-term ability to support entrepreneurial and family-owned companies while respecting their identity and specific governance model. For SEO content focused on the corporate executive linked to BNP Paribas Développement at LNA Santé, the most relevant angle is therefore that of an institutional investor profile, with expertise in governance, external growth, and capital reinforcement.
